Antibe Therapeutics Inc. (ATE)

1.23
0.00(0.00%)
  • Volume:
    6,600
  • Bid/Ask:
    1.22/1.24
  • Day's Range:
    1.21 - 1.23
  • Type:Equity
  • Market:Canada
  • ISIN:CA0370255097
  • CUSIP:037025509

ATE Overview

Prev. Close
1.23
Day's Range
1.21-1.23
Revenue
11.34M
Open
1.21
52 wk Range
0.3-7.52
EPS
-0.64
Volume
6,600
Market Cap
63.05M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
26,774
P/E Ratio
-
Beta
-0.07
1-Year Change
232.43%
Shares Outstanding
51,680,993
Next Earnings Date
Dec. 01, 2021
What is your sentiment on Antibe Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Antibe Therapeutics Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyBuySellSell
Technical IndicatorsBuyBuyBuyStrong SellStrong Sell
SummaryBuyStrong BuyBuyStrong SellStrong Sell

Antibe Therapeutics Inc Company Profile

Antibe Therapeutics Inc Company Profile

Employees
37
Market
Canada

Antibe Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is focused on pain, inflammation and regenerative medicine. The Company's segments include Antibe Therapeutics, and Citagenix, which is a marketer and distributor of regenerative medicines serving the dental and orthopedic market places. The Company's drug design methodologies involve chemically linking a base drug to its hydrogen sulfide-releasing molecule. Its lead compound, ATB-346, combines hydrogen sulfide with naproxen, which is a non-steroidal anti-inflammatory drug (NSAID). The Company's other products include ATB-352, which is indicated for the treatment of severe acute pain, and ATB-340 is a Gastrointestinal (GI)-safe derivative of aspirin. The Company also offers regenerative medical devices, which include PentOS (CGX-283), CGX-227, CGX-443 and URIST (CGX-276), all of which target bone regeneration, and are indicated for oral and maxillofacial surgery.

Read More
  • Take the L sell that sht
    1
    • Antibe sux ass
      1
      • It would have been nice to get the heads up yesterday
        0
        • Wtf happened here?
          0
          • time to sell
            0
            • warrants, derisking before results
              0
              • anybody knows why ATE is falling?
                0
                • Buy out coming soon
                  0
                  • Does anybody know why the stock ran up?
                    1
                    • results of phase 2 study should be coming available soon...
                      0
                    • results of phase 2 study should be coming available soon...
                      0
                    • results of phase 2 study should be coming available soon...
                      0
                  • up
                    0
                    • I think its got way more travelling room to the north. but I'd wait for a pullback to enter. It has entered overbought territory.
                      0
                      • Anyone looking on this stock
                        1
                        • I had it in my paper account. disappointed I missed the hike
                          0
                      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.